



UNITED STATES SEPARTMENT OF COMMERCE Patent and Trademark Office



NOTICE OF ALLOWANCE AND ISSUE FEE DUE

HM22/0702

KEVIN M FARRELL P O BOX 999 YORK HARBOR ME 03911

APPLICATION NO.		FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DA	DATE MAILED	
	09/026.27	6 02/19/ 9 8	017	HAMUD, F	1647	07/02/01	
First Named Applicant	KENTEN,		35	USC 154(b) term ext. =	0 Days.		

TITLE OF INVENTION

UBIQUITIN FUSION-BASED VACCINE SYSTEM

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN.	TYPE	SMALL E	NTITY	FEE DUE		DATE DUE
1 IGN-9601	424-19	92.100	163	UTI	LITY	NO	\$1240	.00	10/02/01

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED</u>.

HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above. If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
 - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
 - B. If the status is the same, pay the FEE DUE shown above.
- If the SMALL ENTITY is shown as NO:
- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- II. All communications regarding this application must give application number and batch number.
 Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

MPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PATENT AND TRADEMARK OFFICE COPY

OL-85 (REV. 10-96) Approved for use through 06/30/99. (0651-0033)



Notice of Allowability



Applicant(\$)

1647

KENTEN et al

Examiner

Fozia Hamud

Art Unit



--The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS (or previously mailed), a Notice of Allowance and Issue Fee Due or other app THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. The initiative of the Office or upon petition by the applicant. See 37 CFR 1.3	propriate communication will be mailed in due course. his application is subject to withdrawal from issue at
1. X This communication is responsive to <u>The amendment filed on 01</u>	
2. X The allowed claim(s) is/are 2-12, 14-19 (now renumbered 1-17)	
3. The drawings filed on are acceptable as for	
4. Acknowledgement is made of a claim for foreign priority under 3	5 U.S.C. § 119(a)-(d).
a) ☐ All b) ☐ Some* c) ☐ None of the:	
1. Certified copies of the priority documents have been received	ved.
2. Certified copies of the priority documents have been received	ved in Application No
3. Copies of the certified copies of the priority documents have application from the International Bureau (PCT Rule 17.2)	2(a)).
*Certified copies not received:	•
5. Acknowledgement is made of a claim for domestic priority under	35 U.S.C. § 119(e).
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communoted below. Failure to timely comply will result in ABANDONMENT of this EXTENDABLE FOR SUBMITTING NEW FORMAL DRAWINGS, OR A SUBSTIT for complying with the REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL I	application. THIS THREE-MONTH PERIOD IS NOT FUTE OATH OR DECLARATION. This three-month period
6. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INITION reason(s) why the oath or declaration is deficient. A SUBSTITUTION of the attached EXAMINER'S AMENDMENT or NOTICE OF INITION OF THE PROPERTY OF THE ATTACH OF THE A	
7. Applicant MUST submit NEW FORMAL DRAWINGS	
(a) including changes required by the Notice of Draftsperson's Pa	atent Drawing Review (PTO-948) attached
1) \square hereto or 2) \square to Paper No	
(b) including changes required by the proposed drawing correction approved by the examiner.	on filed, which has been
(c) including changes required by the attached Examiner's Amen Paper No	dment/Comment or in the Office action of
Identifying indicia such as the application number (see 37 CFR 1.84) drawings should be filed as a separate paper with a transmittal letter	
8. Note the attached Examiner's comment regarding REQUIREMENT	FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
Any reply to this letter should include, in the upper right hand corner, the NUMBER). If applicant has received a Notice of Allowance and Issue Fe the NOTICE OF ALLOWANCE should also be included.	
Attachment(s)	
Notice of References Cited (PTO-892)	2 Notice of Informal Patent Application (PTO-152)
3 Notice of Draftsperson's Patent Drawing Review (PTO-948)	4 Interview Summary (PTO-413), Paper No
5 X Information Disclosure Statement(s) (PTO-1449), Paper No(s).18, 19, 22	6 X Examiner's Amendment/Comment
7 Lagranding Requirement for Deposit of Biological Material	8 L Examiner's Statement of Reasons for Allowance
9 Other	CHRISTINE J. SAOUD PRIMARY EXAMINER Chustin V. Saoud
	('Ausun V. Jasuo

File roby

Page 2

Serial Number: 09/026,276

Art Unit: 1647

1. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Kevin Farrell, on 06/28/2001.

2. The application has been amended as follows:

IN THE Specification:

2a. Please amend the title of the invention to: Ubiquitin Fusion-Based Vaccine System

IN THE CLAIMS:

2b. Please cancel claims 77-80 and 84-100 without prejudice or disclaimer.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fozia Hamud whose telephone number is (703) 308-8891. The examiner can normally be reached on Tuesday-Thursday from 6:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached at (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4227. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Fozia Hamud Patent Examiner Art Unit 1647 June 28, 2001

CHRISTINE J. SAOUD PRIMARY EXAMINER

Ohustine D. Saoud